Reset filters
26 September 2024

In this Community Call, we discussed:

  • Digital spatial profiling identifies distinct molecular signatures of vascular lesions in PAH
  • Phosphodiesterase-5 inhibitor treatment is associated with improved survival in pulmonary hypertension associated with COPD in the PVRI GoDeep meta-registry
PVRI Community Calls
20 September 2024

Recommended therapies for pulmonary arterial hypertension (PAH) have until recently targeted pathways with predominant effects of pulmonary vasodilation.1 The recent addition to treatment options of sotatercept, an activin signaling inhibitor which rebalances pro- and antiproliferative signaling, bolsters a longstanding goal of targeting pathogenic pulmonary vascular remodeling.

Pulmonary Circulation